Celcuity Inc Achieves Significant Clinical Trial Milestone
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 29 2026
0mins
Should l Buy CELC?
Source: Newsfilter
Celcuity Inc's stock rose by 5.19% as it crossed above the 5-day SMA, despite the broader market decline with the Nasdaq-100 down 1.79% and the S&P 500 down 1.08%.
This increase is attributed to the company's recent updates on gedatolisib clinical data, revealing a median progression-free survival (PFS) of 16.6 months in the VIKTORIA-1 trial, significantly outperforming the 1.9 months seen with fulvestrant alone. The positive results highlight the therapy's potential for HR+, HER2- breast cancer patients, suggesting a transformative impact on treatment options.
The implications of this data are substantial, as it not only supports future FDA New Drug Application submissions but also positions Celcuity favorably in the oncology market, potentially attracting more investor interest and enhancing its market valuation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 130.710
Low
94.00
Averages
106.50
High
126.00
Current: 130.710
Low
94.00
Averages
106.50
High
126.00
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ACT Capital Management Acquires New Position in Alumis Worth $4.36 Million
- New Position: On May 8, 2026, ACT Capital Management disclosed a new position in Alumis by acquiring 174,250 shares valued at approximately $4.36 million, indicating strong confidence in the company's future prospects.
- Quarterly Valuation: The position's valuation stood at $3.84 million at quarter-end, reflecting the impact of market price changes and share count, highlighting Alumis's significance in the investment portfolio.
- Stock Performance: Alumis shares surged 350% over the past year, significantly outperforming the S&P 500's 30% gain, showcasing its robust growth potential in the biopharmaceutical sector.
- Clinical Progress: Alumis reported positive Phase 3 data for moderate-to-severe plaque psoriasis in March, with plans to submit a New Drug Application in the second half of 2026, further boosting investor confidence in its drug development pipeline.
See More
Middle East Tensions Weigh on Stock Market Performance
- Market Decline: The S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 1.13%, and the Nasdaq 100 index decreased by 0.21%, reflecting investor concerns over escalating tensions in the Middle East, which dampened market sentiment.
- Oil Price Surge: WTI crude oil prices surged over 4% following exchanges of fire between the US and Iran in the Strait of Hormuz, raising inflation expectations and pushing bond yields higher, with the 10-year T-note yield reaching a five-week high of 4.46%.
- Strong Economic Data: US March factory orders rose by 1.5% month-over-month, exceeding expectations of 0.6%, marking the largest increase in four months, indicating economic resilience that could provide support to the stock market.
- Earnings Optimism: As of Monday, 82% of the 322 S&P 500 companies that reported Q1 earnings exceeded estimates, with projected earnings growth of 12% year-over-year for Q1, although excluding the technology sector, the growth is only 3%, highlighting performance disparities across sectors.
See More
Celcuity (CELC.US) Director Plans to Sell $3.52 Million in Common Stock via Form 144
- Stock Sale Announcement: Celcuity's Director, Dalvey David, plans to sell 25,000 shares of its common stock on May 4.
- Market Value: The total market value of the shares being sold is approximately $3.52 million.
See More
Amazon Launches Supply Chain Services, Pressuring Logistics Stocks
- Logistics Stocks Decline: Amazon's announcement of its own supply chain services has pressured logistics stocks, with GXO Logistics down 11%, UPS falling about 10%, and both FedEx and C.H. Robinson sinking 9%, indicating market concerns over Amazon's competitive threat.
- Berkshire Hathaway's Steady Performance: CEO Greg Abel reassured investors at the annual shareholders meeting, leading to nearly a 1% increase in stock price, which reflects growing investor confidence in the company's future opportunities and alleviates concerns about breaking up the conglomerate.
- Global Business Travel Group Acquisition: Long Lake's $6.3 billion acquisition of Global Business Travel Group signals confidence in AI's potential to reshape the travel sector, resulting in a 57% surge in the company's stock price, showcasing optimistic market expectations for future growth.
- Norwegian Cruise Line Lowers Forecast: Norwegian Cruise Line's stock dropped 8% after it sharply cut its second-quarter and full-year estimates due to skyrocketing fuel prices from the U.S.-Iran conflict, reflecting market concerns about its profitability amid rising operational costs.
See More
US Stock Market Volatility Amid Oil Price Recovery
- Market Volatility: The S&P 500 index fell by 0.04%, the Dow Jones Industrial Average decreased by 0.42%, while the Nasdaq 100 index rose by 0.19%, indicating market fluctuations amid heightened tensions in the Strait of Hormuz, leading to cautious investor sentiment.
- Oil Price Recovery: WTI crude oil prices slightly increased following an unverified report of two missiles hitting a US patrol boat, despite US Central Command stating no US ships were struck, highlighting the market's sensitivity to geopolitical risks.
- Corporate Earnings Optimism: So far, 82% of the 317 S&P 500 companies that reported earnings exceeded expectations, with Q1 earnings projected to rise by 12% year-over-year, demonstrating corporate resilience driven by AI investments, which may support the stock market.
- Interest Rate Expectations Shift: The market discounts only a 3% chance of a 25 basis point rate cut at the upcoming FOMC meeting in June, while the ECB's rate hike expectations stand at 93%, reflecting differing investor outlooks on future monetary policy.
See More
Celcuity Upgraded to Buy with Price Target Raised to $165
- Upgrade Announcement: H.C. Wainwright upgraded Celcuity from ‘Neutral’ to ‘Buy’ and raised its price target from $94 to $165, citing positive Phase 3 trial results that indicate significant potential in breast cancer treatment.
- Price Target Increase: Citizens also raised its price target for Celcuity from $150 to $160 while maintaining an ‘Outperform’ rating, highlighting the drug's promising application in second-line ER+/HER2- breast cancer with an expected progression-free survival of 11-12 months.
- Positive Market Reaction: Celcuity's shares surged over 15% in pre-market trading on Monday, and if these gains hold through the regular session, it would mark the stock's best single-day performance in over six months, reflecting strong market confidence in its new therapy.
- Acquisition Potential: Analysts suggest that Celcuity could become an acquisition target in the oncology sector, as its breast cancer therapy gedatolisib achieved its primary endpoint in the Phase 3 trial, demonstrating significant clinical relevance that could reshape market dynamics.
See More
ACT Capital Management Acquires New Position in Alumis Worth $4.36 Million
- New Position: On May 8, 2026, ACT Capital Management disclosed a new position in Alumis by acquiring 174,250 shares valued at approximately $4.36 million, indicating strong confidence in the company's future prospects.
- Quarterly Valuation: The position's valuation stood at $3.84 million at quarter-end, reflecting the impact of market price changes and share count, highlighting Alumis's significance in the investment portfolio.
- Stock Performance: Alumis shares surged 350% over the past year, significantly outperforming the S&P 500's 30% gain, showcasing its robust growth potential in the biopharmaceutical sector.
- Clinical Progress: Alumis reported positive Phase 3 data for moderate-to-severe plaque psoriasis in March, with plans to submit a New Drug Application in the second half of 2026, further boosting investor confidence in its drug development pipeline.
See More
Middle East Tensions Weigh on Stock Market Performance
- Market Decline: The S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 1.13%, and the Nasdaq 100 index decreased by 0.21%, reflecting investor concerns over escalating tensions in the Middle East, which dampened market sentiment.
- Oil Price Surge: WTI crude oil prices surged over 4% following exchanges of fire between the US and Iran in the Strait of Hormuz, raising inflation expectations and pushing bond yields higher, with the 10-year T-note yield reaching a five-week high of 4.46%.
- Strong Economic Data: US March factory orders rose by 1.5% month-over-month, exceeding expectations of 0.6%, marking the largest increase in four months, indicating economic resilience that could provide support to the stock market.
- Earnings Optimism: As of Monday, 82% of the 322 S&P 500 companies that reported Q1 earnings exceeded estimates, with projected earnings growth of 12% year-over-year for Q1, although excluding the technology sector, the growth is only 3%, highlighting performance disparities across sectors.
See More
Celcuity (CELC.US) Director Plans to Sell $3.52 Million in Common Stock via Form 144
- Stock Sale Announcement: Celcuity's Director, Dalvey David, plans to sell 25,000 shares of its common stock on May 4.
- Market Value: The total market value of the shares being sold is approximately $3.52 million.
See More
Amazon Launches Supply Chain Services, Pressuring Logistics Stocks
- Logistics Stocks Decline: Amazon's announcement of its own supply chain services has pressured logistics stocks, with GXO Logistics down 11%, UPS falling about 10%, and both FedEx and C.H. Robinson sinking 9%, indicating market concerns over Amazon's competitive threat.
- Berkshire Hathaway's Steady Performance: CEO Greg Abel reassured investors at the annual shareholders meeting, leading to nearly a 1% increase in stock price, which reflects growing investor confidence in the company's future opportunities and alleviates concerns about breaking up the conglomerate.
- Global Business Travel Group Acquisition: Long Lake's $6.3 billion acquisition of Global Business Travel Group signals confidence in AI's potential to reshape the travel sector, resulting in a 57% surge in the company's stock price, showcasing optimistic market expectations for future growth.
- Norwegian Cruise Line Lowers Forecast: Norwegian Cruise Line's stock dropped 8% after it sharply cut its second-quarter and full-year estimates due to skyrocketing fuel prices from the U.S.-Iran conflict, reflecting market concerns about its profitability amid rising operational costs.
See More
US Stock Market Volatility Amid Oil Price Recovery
- Market Volatility: The S&P 500 index fell by 0.04%, the Dow Jones Industrial Average decreased by 0.42%, while the Nasdaq 100 index rose by 0.19%, indicating market fluctuations amid heightened tensions in the Strait of Hormuz, leading to cautious investor sentiment.
- Oil Price Recovery: WTI crude oil prices slightly increased following an unverified report of two missiles hitting a US patrol boat, despite US Central Command stating no US ships were struck, highlighting the market's sensitivity to geopolitical risks.
- Corporate Earnings Optimism: So far, 82% of the 317 S&P 500 companies that reported earnings exceeded expectations, with Q1 earnings projected to rise by 12% year-over-year, demonstrating corporate resilience driven by AI investments, which may support the stock market.
- Interest Rate Expectations Shift: The market discounts only a 3% chance of a 25 basis point rate cut at the upcoming FOMC meeting in June, while the ECB's rate hike expectations stand at 93%, reflecting differing investor outlooks on future monetary policy.
See More
Celcuity Upgraded to Buy with Price Target Raised to $165
- Upgrade Announcement: H.C. Wainwright upgraded Celcuity from ‘Neutral’ to ‘Buy’ and raised its price target from $94 to $165, citing positive Phase 3 trial results that indicate significant potential in breast cancer treatment.
- Price Target Increase: Citizens also raised its price target for Celcuity from $150 to $160 while maintaining an ‘Outperform’ rating, highlighting the drug's promising application in second-line ER+/HER2- breast cancer with an expected progression-free survival of 11-12 months.
- Positive Market Reaction: Celcuity's shares surged over 15% in pre-market trading on Monday, and if these gains hold through the regular session, it would mark the stock's best single-day performance in over six months, reflecting strong market confidence in its new therapy.
- Acquisition Potential: Analysts suggest that Celcuity could become an acquisition target in the oncology sector, as its breast cancer therapy gedatolisib achieved its primary endpoint in the Phase 3 trial, demonstrating significant clinical relevance that could reshape market dynamics.
See More
